SHSE:600594 (China)
Â
Class A
Â¥
3.81
-0.010 (-0.26%)
Sep 22
Business Description
Guizhou Yibai Pharmaceutical Co Ltd
SIC : 2834
ISIN : CNE000001H03
Share Class Description:
SHSE:600594: Class ATotal Employee Number:
4,832Compare
Compare
Traded in other countries / regions
600594.China Index Membership
SSE Composite Index IPO Date
2004-03-23Description
Guizhou Yibai Pharmaceutical Co Ltd is a Chinese pharmaceutical company engaged in the research, development, production, and sale of prescription and over-the-counter medicines. Its product portfolio spans therapeutic areas including oncology, cardio-cerebrovascular, respiratory, anti-rheumatic, digestive, pediatric, gynecological, andrological, anti-infective, and anti-inflammatory treatments, along with analgesics and tonic medicines. The company markets its drugs primarily to hospitals, clinics, and pharmacies across China, with distribution through regional and national pharmaceutical wholesalers. Its revenue comes mainly from the sale of finished pharmaceutical products, supported by in-house research and development and manufacturing at its production facilities in Guizhou Province. The company also produces traditional Chinese medicine formulations alongside chemical drugs, reflecting its position in China's domestic pharmaceutical market.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.63 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.33 | |||||
Debt-to-EBITDA | -2.05 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.07 | |||||
Beneish M-Score | -3.46 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.7 | |||||
3-Year EBITDA Growth Rate | 11.9 | |||||
3-Year EPS without NRI Growth Rate | 11.2 | |||||
3-Year FCF Growth Rate | 116.2 | |||||
3-Year Book Growth Rate | -8.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.1 | |||||
9-Day RSI | 39.6 | |||||
14-Day RSI | 43.08 | |||||
3-1 Month Momentum % | 26.37 | |||||
6-1 Month Momentum % | -1.26 | |||||
12-1 Month Momentum % | -8.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.7 | |||||
Quick Ratio | 1.03 | |||||
Cash Ratio | 0.54 | |||||
Days Inventory | 305.45 | |||||
Days Sales Outstanding | 37.05 | |||||
Days Payable | 49.79 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 58.15 | |||||
Operating Margin % | -8.74 | |||||
Net Margin % | -25.01 | |||||
EBITDA Margin % | -21.57 | |||||
FCF Margin % | 7.42 | |||||
OCF Margin % | 9.65 | |||||
ROE % | -17.22 | |||||
ROA % | -10.83 | |||||
ROIC % | -4.83 | |||||
3-Year ROIIC % | 36.43 | |||||
ROC (Joel Greenblatt) % | -17.16 | |||||
ROCE % | -12.38 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.93 | |||||
PB Ratio | 1.43 | |||||
Price-to-Tangible-Book | 1.67 | |||||
Price-to-Free-Cash-Flow | 25.66 | |||||
Price-to-Operating-Cash-Flow | 19.72 | |||||
EV-to-EBIT | -9.9 | |||||
EV-to-EBITDA | -21.67 | |||||
EV-to-Revenue | 2.14 | |||||
EV-to-FCF | 28.8 | |||||
Price-to-GF-Value | 1.31 | |||||
Price-to-Projected-FCF | 1.03 | |||||
Price-to-Median-PS-Value | 1.27 | |||||
| Price-to-Net-Current-Asset-Value | 16.57 | |||||
Earnings Yield (Greenblatt) % | -10.1 | |||||
FCF Yield % | 3.87 | |||||
Forward Rate of Return (Yacktman) % | 0.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guizhou Yibai Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,559.185 | ||
| EPS (TTM) (Â¥) | -0.497 | ||
| Beta | 0.872 | ||
| 3-Year Sharpe Ratio | -0.26 | ||
| 3-Year Sortino Ratio | -0.36 | ||
| Volatility % | 35.09 | ||
| 14-Day RSI | 43.08 | ||
| 14-Day ATR (Â¥) | 0.192677 | ||
| 20-Day SMA (Â¥) | 3.8245 | ||
| 12-1 Month Momentum % | -8.82 | ||
| 52-Week Range (Â¥) | 2.85 - 5.27 | ||
| Shares Outstanding (Mil) | 784.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guizhou Yibai Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guizhou Yibai Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| 2:1 Stock Split | 2015-07-16 | 26.96 (-12.75%) | ||
| 1.5:1 Stock Split | 2010-10-15 | 7.70 (-1.58%) | ||
| 1.3:1 Stock Split | 2008-07-03 | 2.29 (+1.02%) | ||
| 1.5:1 Stock Split | 2007-09-17 | 3.94 (-3.07%) | ||
| 1.5:1 Stock Split | 2006-06-05 | 2.17 (-6.01%) | ||
| 1.3:1 Stock Split | 2005-12-05 | 1.58 (+0.00%) | ||
| 1.2:1 Stock Split | 2005-06-09 | 1.04 (+9.62%) |
Show
Entries
Guizhou Yibai Pharmaceutical Co Ltd Frequently Asked Questions
What is Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594)'s stock price today?
The current price of SHSE:600594 is ¥3.81. The 52 week high of SHSE:600594 is ¥5.27 and 52 week low is ¥2.85.
When is next earnings date of Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594)?
The next earnings date of Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594) is .
Does Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594) pay dividends? If so, how much?
Guizhou Yibai Pharmaceutical Co Ltd(SHSE:600594) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers